A clinical study was conducted to see whether an antibody called denosumab is effective in treatment of osteoporosis of postmenopausal women, as reported in the article "Denosumab in Postmenopausal Women with Low Bone Mineral Density (New England Journal of Medicine, Vol. 354, No. 8, pp. 821-831) by M. McClung et al. Postmenopausal women with osteoporosis were randomly assigned into groups that received either a placebo, or a six-month regimen of Denosumab at doses of 14 mg, 60 mg, 100 mg, or 210 mg. The following table provides summary statistics for the body-mass indexes (BMI) of the women in each treatment group.

At the 10% significance level, do the data provide sufficient evidence to conclude that a difference exists in mean BMI for women in the five different treatment groups? For the degrees of freedom in this exercise:

Transcribed Image Text:

Treatment | ni | Placebo 14 mg 60 mg 100 mg 210 mg 46 25.9 4.3 54 25.8 5.3 47 27.5 5.8 42 26.0 4.6 47 25.9 4.3 α | 0.10 0.05 0.025 0.01 0.005 1.97 2.41 2.84 3.40 3.82